The global Rheumatic-Heart Disease Management market size is expected to be valued at USD 1.31 Billion in 2023. With the continuous improvements in drugs and biotechnology, the overall demand for Rheumatic-Heart Disease Management is projected to grow at a CAGR of 4.5% between 2023 and 2033, totaling around USD 2.04 Billion by 2033.
| Data Points | Key Statistics |
|---|---|
| Rheumatic-Heart Disease Management Market Value 2023 | USD 1.31 Billion |
| Rheumatic-Heart Disease Management Market Projected Value (2033) | USD 2.04 Billion |
| Rheumatic-Heart Disease Management Market CAGR (2023 to 2033) | 4.5% |
According to the analysis of Future Market Insights, rheumatic fever is an autoimmune inflammatory disease that can develop as a complication of inadequately treated strep throat. Strep throat is a condition caused by group a of the Streptococcus bacterium. Rheumatic fever is common in the age group of 5 to 15 years, but adults can also have the condition. In certain cases, rheumatic fever can cause long-term damage to the heart and heart valves.
According to the World Health Organization (WHO) report published in April 2018, approximately 30 million people are affected by rheumatic heart disease globally. The increasing occurrences of strep throat and the growing prevalence of rheumatic fever are the major factors that are anticipated to boost the growth of the rheumatic heart disease management market over the analysis period. Additionally, another factor including increasing government expenditure for the healthcare sector is also expected to contribute to the market growth in the near future.
Explore FMI!
Book a free demo
The global demand for Rheumatic-Heart Disease Management is projected to increase at a CAGR of 4.5% during the forecast period between 2023 and 2033, reaching a total of USD 2.04 Billion in 2033, according to a report from Future Market Insights (FMI). From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 2.1%.
According to Future Market Insights, a market research and competitive intelligence provider, the Rheumatic-Heart Disease Management market was valued at USD 1.25 Billion in 2022.
In developing economies, rheumatic fever is highly prevalent and remains one of the major causes of rheumatic heart disease. Rheumatic fever is a major cause of mortality among people aged 50 years and above. According to the United Nations Department of Economic and Social Affairs, in 2015, the global population aged 60 years and above was approximately 901 million, and the number is expected to increase significantly over the analysis period.
The population aged 50 years and above has a higher incidence of rheumatic heart disease and mortality rates as compared to younger people. The incidence rate of rheumatic fever is higher in developing countries as compared to developed countries.
According to the Centers for Disease Control and Prevention (CDC), about 23% of adults in the USA, which is over 54 million people, have arthritis. By 2040, the disease is expected to affect 78 million adults in the country. Rheumatic fever is a leading cause of disability. The direct medical costs associated with the disease are over USD 81 Million annually. This disease is more common in women than in men.
Increasing prevalence of Strep Throat and Rheumatic Fever to Fuel the Market Growth
The rising incidences of strep throat are one of the major factors that are projected to augment the growth of the rheumatic heart disease management market during the forecast period. Rheumatic fever is an autoimmune inflammatory disease that can develop as a result of strep throat that hasn't been properly treated. Strep throat is a bacterial infection caused by the Streptococcus bacteria of group A.
It is highly common in low- and middle-income countries, due to a lack of proper sanitation, and healthcare awareness in these countries. According to the statistics by the World Health Organization (WHO), rheumatic heart diseases, such as rheumatic myocarditis is responsible for over 288 348 deaths each year, as of 2020.
Rise in Research & Development Activities to Accelerate the Market Growth
The growth of the rheumatic heart disease management market will also be driven by an increase in the number of research and development activities, which in turn are expected to provide beneficial opportunities for market growth in the coming years. In addition, factors such as a rise in government initiatives, improved healthcare infrastructure, and an increase in the number of emerging markets are expected to create lucrative avenues for market growth during the forecast period.
Additionally, a rise in investment in the healthcare sector in developing countries, and government initiatives to curb the spread of streptococcus bacteria, are expected to accelerate the market growth. For instance, in 2018, the WHO launched a coordinated global response for rheumatic heart disease and rheumatic fever, with the help of WHO’s regional offices. The program includes a road map for the distribution of medicines, vaccines, and other healthcare products by 2023.
Lack of Awareness in Low-and-Middle-Income Countries to Restrain the Market Growth
Lack of Awareness regarding the treatment of rheumatic heart disease is one of the major factors that is expected to impede the growth of the Rheumatic-Heart Disease Management Market over the analysis period.
Moreover, the dearth of skilled professionals and lack of healthcare infrastructure in developing economies are other factors that are expected to challenge market growth. In addition, the high cost associated with the treatment of rheumatic heart disease will obstruct the growth rate of the market.
Fewer Treatment Options to Limit the Market Growth
Factors including fewer treatment options available for the treatment of rheumatic heart disease management are likely to hinder the growth of the Rheumatic-Heart Disease Management market in the forthcoming years.
Moreover, rheumatic heart disease can be prevented by effective management of streptococcal sore throat, however, treatment at this early stage is often not achieved. Families may not have the time or money to access a healthcare facility, or may not seek care due to low awareness of the potential risk of untreated ‘strep throat’. Healthcare workers may also not have the necessary knowledge to appropriately diagnose and manage ‘strep throat’. If left untreated, rheumatic fever may then ensue. This in turn is anticipated to hamper the market growth during the forecast period.
Increase in Prevalence of Rheumatic Fever in the Region to Fuel the Market Growth
The Rheumatic-Heart Disease Management Market in North America is expected to accumulate the highest market share of 45% in 2023.
Factors such as the increasing prevalence of rheumatic fever and the growing focus of major key players on novel technology are expected to boost the regional market growth over the analysis period. Favorable health reimbursement, an increasing number of valve repair and replacement procedures, and a rising obese population are other factors responsible for the market growth in the region.
According to the American Heart Association, 90,000 valve substitutes are implanted in the USA every year. This is poised to surge the demand for prosthetic heart valves in North America, which in turn is anticipated to fuel the market growth. The region is expected to hold the highest CAGR of 4.4% during the forecast period.
Rising Prevalence of Rheumatic Heart Disease in the Region to Fuel the Market Growth
The Rheumatic-Heart Disease Management Market in Europe is expected to accumulate the highest market share of 44% in 2023.
In Europe, the market is estimated to expand, attributed to the factors such as the increasing prevalence of rheumatic heart disease and the gradual shift towards minimally invasive procedures. According to the European Society of Cardiology, in 2017, the average proportion of males and females with elevated blood pressure in Europe was 28% and 20% respectively. This is expected to foster the prosthetic Heart Valves Market in Europe.
Moreover, the regional market is projected to grow, owing to the rising geriatric and obese population, rapid adoption of tissue valves, and active government support. The region is expected to hold the highest CAGR of 4.3% during the forecast period.
Valve Segment to beat Competition in Untiring Market
On the basis of type, the global Rheumatic-Heart Disease Management market is dominated by the Valve Segment, which accounts for a share of 46%. The segment is expected to hold a CAGR of 4.4% over the analysis period.
The high segment’s growth is attributed to factors such as the introduction of new products in the market. Already, the introduction of tissue valves has revolutionized the prosthetic heart valves, which in turn is expected to boost the segment’s growth.
Now, with the launch of products that are minimally invasive and sutureless, the rheumatic heart disease market is expected to gain significant traction. In addition, many manufacturers are carrying out dedicated research and clinical trial for the development of innovative heart valves.
Hospitals Segment to Drive the Rheumatic-Heart Disease Management Market
Based on the Application, the hospital's segment is expected to witness a significant growth of 46% in 2022, and the trend is expected to continue during the forecast period, expanding at a rapid rate of 4.3% CAGR over the analysis period.
The segment’s significant growth is attributed to the factors such as the increasing number of procedures in hospitals, favorable health reimbursement, and improving government guidelines for the management of vulvar diseases, which are contributing to the expansion of the market growth.
Rheumatic-Heart Disease Management Market startup players are adopting various marketing strategies such as new product launches, geographical expansion, mergers and acquisitions, partnerships, and collaboration to identify the interest of potential patients and create a larger customer base. For instance,
Prominent players in the Rheumatic-Heart Disease Management market are F. Hoffmann-La Roche Ltd., Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi, Pfizer Inc., GlaxoSmithKline plc., Novartis AG, Bayer AG, Eli Lilly and Company, Merck & Co., Inc., Allergan, AstraZeneca, AbbVie Inc., Johnson & Johnson Private Limited, Cipla Inc., Abbott, Merck KGaA, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma, Dr. Reddy’s Laboratories Ltd., Glenmark Pharmaceuticals Limited, Amneal Pharmaceuticals LLC., and Bayer AG, among others.
Recent Developments:
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR of 4.5% from 2023 to 2033 |
| Market Value in 2023 | USD 1.31 Billion |
| Market Value in 2033 | USD 2.04 Billion |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Billion and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Type, Application, Region |
| Regions Covered | North America; Europe; Europe; Latin America; Middle East & Africa |
| Key Countries Profiled | USA, Canada, Brazil, Mexico, Germany, United Kingdom, France, Spain, Italy, China, Japan, South Korea, Malaysia, Singapore, Australia, New Zealand, GCC Countries, South Africa, Israel |
| Key Companies Profiled | F. Hoffmann-La Roche Ltd.; Mylan N.V.; Teva Pharmaceutical Industries Ltd.; Sanofi; Pfizer Inc.; GlaxoSmithKline plc.; Novartis AG; Bayer AG; Eli Lilly and Company; Merck & Co., Inc.; Allergan; AstraZeneca; AbbVie Inc.; Johnson & Johnson Private Limited; Cipla Inc.; Abbott; Merck KGaA; Sun Pharmaceutical Industries Ltd.; Aurobindo Pharma; Dr. Reddy’s Laboratories Ltd.; Glenmark Pharmaceuticals Limited; Amneal Pharmaceuticals LLC.; Bayer AG |
The market is valued at USD 1.31 billion in 2023.
F. Hoffmann-La Roche Ltd., Mylan N.V., and Teva Pharmaceutical Industries Ltd. are the leading industry players.
The industry is set to surge at a CAGR of 4.5% from 2023 to 2033.
North America is likely to generate 45% revenue in 2023.
Rising incidence of strep throat and rheumatic fever driving the expansion of the market
Home Respiratory Therapy Market – Growth & Forecast 2025 to 2035
Veterinary Auto-Immune Therapeutics Market Growth - Trends & Forecast 2025 to 2035
Radial Compression Devices Market Growth - Trends & Forecast 2025 to 2035
Digital Telepathology Market is segmented by Application and End User from 2025 to 2035
Suture Anchor Devices Market Is Segmented by Product Type, Material Type, Tying and End User from 2025 to 2035
Home Infusion Therapy Devices Market - Growth & Forecast 2025 to 2035
Rheumatic-Heart Disease Management Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
